$44.56
0.71.60%
At Close: -
$44.56
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Celldex Therapeutics (NASDAQ:CLDX) Stock, Analyst Ratings, Price Targets, Forecasts
Celldex Therapeutics Inc has a consensus price target of $66.71 based on the ratings of 9 analysts. The high is $90 issued by Guggenheim on February 27, 2024. The low is $27 issued by Wells Fargo on November 10, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Cantor Fitzgerald, and HC Wainwright & Co. on July 16, 2024, June 18, 2024, and June 3, 2024, respectively. With an average price target of $75.67 between HC Wainwright & Co., Cantor Fitzgerald, and HC Wainwright & Co., there's an implied 69.81% upside for Celldex Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Cantor Fitzgerald
Guggenheim
Wells Fargo
SVB Leerink
1calculated from analyst ratings
Analyst Ratings for Celldex Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/16/2024 | Buy Now | 79.53% | HC Wainwright & Co. | Joseph Pantginis | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 06/18/2024 | Buy Now | 50.36% | Cantor Fitzgerald | Kristen Kluska | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 06/11/2024 | Buy Now | — | Wolfe Research | Andy Chen | — | Initiates | → Outperform | Get Alert |
| 06/03/2024 | Buy Now | 79.53% | HC Wainwright & Co. | Joseph Pantginis | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2024 | Buy Now | 79.53% | HC Wainwright & Co. | Joseph Pantginis | → $80 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | 79.53% | HC Wainwright & Co. | Joseph Pantginis | → $80 | Reiterates | Buy → Buy | Get Alert |
| 04/17/2024 | Buy Now | 79.53% | HC Wainwright & Co. | Joseph Pantginis | → $80 | Reiterates | Buy → Buy | Get Alert |
| 03/22/2024 | Buy Now | 50.36% | Cantor Fitzgerald | Kristen Kluska | → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 02/27/2024 | Buy Now | 101.97% | Guggenheim | Yatin Suneja | $72 → $90 | Maintains | Buy | Get Alert |
| 12/20/2023 | Buy Now | — | TD Cowen | Yaron Werber | — | Initiates | → Outperform | Get Alert |
| 11/10/2023 | Buy Now | -39.41% | Wells Fargo | Derek Archila | → $27 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 11/06/2023 | Buy Now | 79.53% | HC Wainwright & Co. | Joseph Pantginis | $73 → $80 | Maintains | Buy | Get Alert |
| 11/03/2023 | Buy Now | 16.7% | Cantor Fitzgerald | Kristen Kluska | $54 → $52 | Maintains | Overweight | Get Alert |
| 10/12/2023 | Buy Now | 21.18% | Cantor Fitzgerald | Kristen Kluska | → $54 | Reiterates | Overweight → Overweight | Get Alert |
| 09/27/2023 | Buy Now | 21.18% | Cantor Fitzgerald | Kristen Kluska | → $54 | Reiterates | Overweight → Overweight | Get Alert |
| 08/22/2023 | Buy Now | -52.87% | Wells Fargo | Derek Archila | → $21 | Initiates | → Underweight | Get Alert |
| 08/16/2023 | Buy Now | 21.18% | Cantor Fitzgerald | Kristen Kluska | → $54 | Reiterates | Overweight → Overweight | Get Alert |
| 08/10/2023 | Buy Now | 63.82% | HC Wainwright & Co. | Joseph Pantginis | → $73 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 63.82% | HC Wainwright & Co. | Joseph Pantginis | → $73 | Reiterates | Buy → Buy | Get Alert |
| 06/12/2023 | Buy Now | 63.82% | HC Wainwright & Co. | Joseph Pantginis | → $73 | Reiterates | Buy → Buy | Get Alert |
| 05/31/2023 | Buy Now | 63.82% | HC Wainwright & Co. | Joseph Pantginis | → $73 | Reiterates | → Buy | Get Alert |
| 05/05/2023 | Buy Now | 21.18% | Cantor Fitzgerald | Kristen Kluska | $55 → $54 | Maintains | Overweight | Get Alert |
| 05/05/2023 | Buy Now | 63.82% | HC Wainwright & Co. | Joseph Pantginis | → $73 | Reiterates | → Buy | Get Alert |
| 03/22/2023 | Buy Now | 63.82% | HC Wainwright & Co. | Joseph Pantginis | → $73 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | 63.82% | HC Wainwright & Co. | Joseph Pantginis | → $73 | Reiterates | → Buy | Get Alert |
| 02/27/2023 | Buy Now | 63.82% | HC Wainwright & Co. | Joseph Pantginis | → $73 | Reiterates | → Buy | Get Alert |
| 11/11/2022 | Buy Now | 41.38% | Guggenheim | Yatin Suneja | $68 → $63 | Maintains | Buy | Get Alert |
| 08/09/2022 | Buy Now | 43.63% | SVB Leerink | Thomas Smith | $68 → $64 | Maintains | Outperform | Get Alert |
| 07/01/2022 | Buy Now | 63.82% | HC Wainwright & Co. | Joseph Hafling | $60 → $73 | Maintains | Buy | Get Alert |
| 09/17/2021 | Buy Now | 48.11% | Jefferies | Chris Howerton | — | Initiates | → Buy | Get Alert |
| 09/13/2021 | Buy Now | 34.65% | HC Wainwright & Co. | Joseph Pantginis | $54 → $60 | Maintains | Buy | Get Alert |
| 09/10/2021 | Buy Now | 52.6% | SVB Leerink | Thomas Smith | — | Initiates | → Outperform | Get Alert |
| 08/06/2021 | Buy Now | 21.18% | HC Wainwright & Co. | Joseph Pantginis | $50 → $54 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Celldex Therapeutics (CLDX) stock?
The latest price target for Celldex Therapeutics (NASDAQ:CLDX) was reported by HC Wainwright & Co. on July 16, 2024. The analyst firm set a price target for $80.00 expecting CLDX to rise to within 12 months (a possible 79.53% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Celldex Therapeutics (CLDX)?
The latest analyst rating for Celldex Therapeutics (NASDAQ:CLDX) was provided by HC Wainwright & Co., and Celldex Therapeutics reiterated their buy rating.
When was the last upgrade for Celldex Therapeutics (CLDX)?
The last upgrade for Celldex Therapeutics Inc happened on November 10, 2023 when Wells Fargo raised their price target to $27. Wells Fargo previously had an underweight for Celldex Therapeutics Inc.
When was the last downgrade for Celldex Therapeutics (CLDX)?
There is no last downgrade for Celldex Therapeutics.
When is the next analyst rating going to be posted or updated for Celldex Therapeutics (CLDX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Celldex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Celldex Therapeutics was filed on July 16, 2024 so you should expect the next rating to be made available sometime around July 16, 2025.
Is the Analyst Rating Celldex Therapeutics (CLDX) correct?
While ratings are subjective and will change, the latest Celldex Therapeutics (CLDX) rating was a reiterated with a price target of $80.00 to $80.00. The current price Celldex Therapeutics (CLDX) is trading at is $44.56, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.